Table of ContentsView AllTable of ContentsGoals of TreatmentTypes of TreatmentsLines of TreatmentFor MenThe Best TreatmentQuestions to Ask YourselfPrognosisAdvocating for YourselfNext in Metastatic Breast Cancer Guide GuideChemotherapy for Metastatic Breast Cancer
Table of ContentsView All
View All
Table of Contents
Goals of Treatment
Types of Treatments
Lines of Treatment
For Men
The Best Treatment
Questions to Ask Yourself
Prognosis
Advocating for Yourself
Next in Metastatic Breast Cancer Guide Guide
Before talking about all of the specific treatments which you may choose formetastatic breast cancer, it helps to talk about the types of treatments, the goals of treatment, and what particular treatments are often used first to address metastatic cancer.
You may be wondering how you can understand which treatments are best if you don’t have a background in medicine, but itispossible to learn enough to make the choices that are best for you as an individual. Let’s look at the factors to consider when choosing a treatment, ways to learn what you need to know to make an educated decision, the importance of getting a second opinion (or at least a remote second opinion) and more.
Unlike early-stage breast cancers, it’s not possible to cure metastatic breast cancer, but it’s still important to consider your goals in treatment.
For example, some people wish to try to live as long as possible with their cancer no matter the side effects. Others may instead feel the quality of their life is more important than quantity, and prefer treatments with fewer side effects.
We wish that everyone could have the goal of living long term with metastatic breast cancer, but at least for now, that isn’t an option for many people. With metastatic cancer, your quality of life becomes very important, but what this means can vary significantly from person to person.
As you think of your options, consider these goals:Will this treatment prolong my life?Will this treatment delay the progression of my cancer?How will this treatment affect my quality of life? Is it expected to improve the symptoms I’m experiencing?If there are side effects, which might I find most tolerable and least tolerable?
As you think of your options, consider these goals:
Even though we now have many different types of treatment for cancer, these can be broken down into two main categories.
Local Treatments
Local treatmentsaddress cancer in the place in which it begins (or in a single metastasis to an organ.) These treatments include:
Systemic Treatments
In contrast, these treatments address cancer cells wherever they happen to be in the body. These include:
For metastatic breast cancer, systemic treatments play the largest role in treatment. Local treatments such as surgery or radiation are used primarily to treat metastases when these are causing symptoms, such as bone metastases which pose the risk of fractures or metastases to the skin or chest wall which are bleeding and painful.
Many people wonder why breast surgeries such as alumpectomyormastectomyare not often done in people who have metastatic breast cancer, at least for the 5% to 10% of people who have metastatic cancer at the time of diagnosis. The reasoning for this is that with metastases, the cancer has already spread well beyond the breast.
These treatments are unable to potentially cure cancer that has spread. Instead, surgery—due to recovery times and immune system suppression—might mean delaying systemic therapies, which ultimately play the largest role in treating your cancer.
Mark Kostich / Getty Images
You will probably hear your healthcare provider talk about “first-line treatment,” “second-line treatment,” and so forth. This term simply means the first treatment or treatments, second treatments, and so on which may be used sequentially to treat your cancer.
It’s very common with metastatic breast cancer to have several different “lines” of treatment. First-line treatment is usually selected based on what treatments are most likely to be successful with the fewest side effects, but there are many options available.
Typical First-Line Treatments
Everyone with metastatic cancer is different, and every cancer is different so it is difficult to talk about “typical” cancer treatment. That said, the first treatments chosen for metastatic cancer are often related to thehormone receptor statusof your cancer.
These treatment approaches will depend on your receptor status after a “rebiopsy” of your tumor or a metastasis, not what your receptor status was when you were first diagnosed if your tumor is a recurrence. If your original cancer was estrogen receptor positive, it may now be negative, and vice versa.
Remember that the goal of treatment for metastatic cancer is usually to use the least amount of treatment possible to stabilize and control the disease. This is different than the “curative” approach used with most early-stage breast cancers.
Examples of possible first-line treatments based on receptor status include the following.
Estrogen Receptor (ER) Positive Metastatic Breast Cancer
The first treatment for estrogen receptor-positive breast cancer is usually hormonal therapy. The choice of drugs will depend on whether you were on hormonal treatment when your cancer returned.
For postmenopausal women, aromatase inhibitors can be used alone or with specific enzyme inhibitors. If your tumor recurred while on anaromatase inhibitor, a different option may be using the anti-estrogen drug Faslodex (fulvestrant).
If your tumor is estrogen receptor positive but is progressing rapidly, there are several options. If your tumor is also HER 2 positive, a HER 2 targeted therapy may be added to hormonal therapy. Chemotherapy may also be used in addition to hormonal therapy for those who have tumors which are growing rapidly.
If you have significant symptoms related to metastases, other treatments may be added in as well. For bone metastases, radiation therapy or a bone-modifying drug may be used to lower the risk of a fracture,spinal cord compression, or to treat severe pain.
Likewise, metastases to the lungs causing bleeding or obstruction, or brain metastases which are causing significant symptoms may also be treated with local therapies such as radiation or surgery.
HER2 Positive Metastatic Breast Cancer
If you have a tumor which is estrogen receptor positive and HER 2 positive, first-line treatment may begin with hormonal treatment alone or the combination of a hormonal drug and a HER 2 positive drug.
First-line treatment for HER 2 positive metastatic breast cancer also depends on whether or not you were being treated with one of these medications when you experienced a recurrence. If your cancer recurred while on Herceptin, one of the other HER 2 medications may be used. If your tumor is growing rapidly, chemotherapy may be considered.
As with estrogen receptor positive tumors, symptomatic metastases may require local treatment as well. For example, painful bone metastases or metastases which increase the risk that you could fracture a bone may be treated with radiation therapy or a bone-modifying agent.
Treatment Options for Metastatic HER2 Positive Breast Cancer
Triple Negative Breast Cancer
Triple negative metastatic breast cancer is more difficult to treat in general than breast cancers which are estrogen receptor or HER 2 positive, but there are still options.
Chemotherapy is often used first line for these cancers, and the choice of medications often depends on whether chemotherapy was used previously.
Metastatic breast cancer in men has several important differences, but in general, the same approach is taken. Treatment may begin with tamoxifen for those who have estrogen receptor-positive tumors, or with chemotherapy.
What do you need to know in order to make the best decisions about your treatment?
The first step is educating yourself about your disease. Read through the information provided here, and any information you received from your cancer center.
Keep a running list of questions to ask your oncologist, and bring them with you to each appointment. If you are still finding it hard to understand something, ask again.
There is a lot of information to digest in a short amount of time and, combined with the difficult emotions that go with a metastatic cancer diagnosis, your oncologist will not get upset if you need to ask the same questions over and over again. That is normal.
Breast Cancer Healthcare Provider Discussion GuideGet our printable guide for your next healthcare appointment to help you ask the right questions.Download PDFEmail AddressSign UpThank you, {{form.email}}, for signing up.There was an error. Please try again.
Get our printable guide for your next healthcare appointment to help you ask the right questions.
Download PDF
Email AddressSign UpThank you, {{form.email}}, for signing up.There was an error. Please try again.
Sign Up
Thank you, {{form.email}}, for signing up.
There was an error. Please try again.
Talk to your friends and family and ask for their input—but the ultimate decisions are up to you. This can be a challenging time, especially if members of your family are not in agreement with your decisions.
Listen to your loved ones and thank them for their input, but remind them, if needed, that you need to choose the path which best honors your own needs and wishes for your care.
Factors That Influence Choice
There are many factors which may be considered in choosing the right treatment for your cancer, both initially, and as time goes on. Some of these include:
Second Opinions
While many people are concerned that getting a second opinion could harm their relationship with their oncologist, it is not only expected, but most oncologists would request a second opinion themselves if diagnosed with metastatic cancer.
When choosing a healthcare provider for a second opinion, it’s a good idea to find one who is not part of the same group. Ideally, requesting an opinion at one of the largerNational Cancer Institute-designated cancer centersoften offers the chance to see an oncologist who specializes in breast cancer. Support communities are sometimes a good place to learn about the centers that excel in breast health.
Getting a second opinion does not mean that you will have to travel to that center for treatment. You may not ever need to travel to see one of these specialists. Often times, a second-opinion healthcare provider can work with your local oncologist to offer guidance and recommendations. Many of the larger cancer centers now offer “remote second opinions,” in which a specialist can look at your medical history, pathology results, and imaging studies, and talk to you over the phone about recommendations.
Some centers that offer remote second opinions include:
For young women (less than age 45) and women who develop lung cancer while pregnant, theUniversity of Colorado Cancer Center(in Aurora, Colorado) offers remote second opinions.
Remote second opinions are becoming more common, so you can check to see if they are offered at the cancer center you are considering for a second opinion.
You’ll have many questions to ask with regard to specific treatments, but you may want to begin considering some questions even before entertaining different options, such as:
Prognosis With/Without Treatment
Some people want to know their prognosis—the “average” outcome for someone with their disease. Other people don’t want to know, and that is fine as well. The truth is that healthcare providers can’t really tell how any one person will do after they are diagnosed with metastatic breast cancer.
Statistics can give us some idea about how a person will do with a particular treatment, but statistics pose several problems. One is that statistics are numbers, not people. We can talk about the numbers of people, on average, who live a year or 10 years with metastatic breast cancer, but we do not have any way of predicting who those people will be.
Another reason statistics fail us is that they are a measure of how people did in the past.
Treatments for metastatic breast cancer are improving, and we don’t really know how someone will do with the new treatments. Many of the statistics we use to judge prognosis are at least five years old. Yet many of the drugs available for metastatic breast cancer were not available five years ago.
At the current time (based, of course, on statistics) the median survival for metastatic breast cancer (including all types) with treatment is considered to be 18 to 24 months. This means that 24 months after diagnosis, half will have died and half will still be alive. Research suggests that the relative 5-year survival rate for metastatic breast cancer has increased to an estimated 36% in recent years, thanks to improved treatment options.There are also many people who have been living with metastatic breast cancer for 10 years or more.
A final thought to keep in mind is that we are truly making progress in the treatment of metastatic breast cancer.Clinical trialsstudying everything from immunotherapy to cancer vaccines for breast cancer are going on right now. It’s hoped that these new categories of treatments will soon be changing old breast cancer statistics for the better.
The best place to begin talking about treatment is your role as an essential member of your healthcare team. You’ve probably already heard that it’s important tobe your own advocatein your care, but what does that really mean?
Being your own advocate means taking an active role in the decisions that go along with your treatment. It means asking questions when you don’t understand something, and continuing to ask until you do understand.
When we talk about being your own advocate with cancer we’re not implying that you will have an adversarial relationship with your oncologist and other members ofyour healthcare team. In contrast, being your own advocate enables you to help your oncologist understand what is most important to you as a person.
In the past, few choices often existed for people diagnosed with metastatic cancer. This has changed tremendously in recent years, and there now may be several different options which could equally meet your goals of treatment.
You won’t be asked to choose between a treatment that is expected to work well with few side effects and one that doesn’t work or has major side effects. The truth is that many of these choices will come down to differences in your own personal needs.
For example, you may need to choose between receiving treatment near your home or at a cancer center out of town, or perhaps make the choice between two different sets of side effects.
Some people find it more difficult than others to advocate for themselves. If you’re ordinarily soft-spoken and quiet—a peacemaker perhaps—you may find it hard to let your healthcare team know when things aren’t going as you would wish. If this fits your personality, it’s often helpful to choose a friend or family member to advocate for you and ask any difficult questions you may find hard to ask.
A Word From Verywell
The examples of possible first-line treatments above are only examples, and your oncologist may recommend a different approach based on the characteristics of your unique tumor. Many drugs are being evaluated in clinical trials, and one of these approaches may offer a different approach.
The important thing is to talk with your healthcare provider about why certain drugs would be recommended and to understand these choices as well as possible alternatives. Many people also find it helpful to ask about the treatments which would be recommended if this particular regimen does not control their tumor.
Being one step ahead in your mind may help you to cope just a little easier with the anxiety related to the unknowns ahead.
9 SourcesVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Liedtke C, Kolberg H.Systemic therapy of advanced/metastatic breast cancer—Current evidence andfFuture concepts.Breast Care. 2016;11(4):275-281. doi:10.1159/000447549Rashid OM, Takabe K.Does removal of the primary tumor in metastatic breast cancer improve survival?J Womens Health (Larchmt). 2014;23(2):184-188. doi:10.1089/jwh.2013.4517Hirata T, Shimizu C, Yonemori K, et al.Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer.Br J Cancer. 2009;101(9):1529-1536. doi:10.1038/sj.bjc.6605360American Cancer Society.Hormone therapy for breast cancer.Larionov AA.Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients.Front Oncol. 2018;8:89. doi:10.3389/fonc.2018.00089Food and Drug Administration.Enhertu label.Chue BM, La Course BD.Case report of long-term survival with metastatic triple-negative breast carcinoma: Treatment possibilities for metastatic disease.Medicine (Baltimore). 2019;98(16):e15302. doi:10.1097/MD.0000000000015302Kurian AW, Friese CR, Bondarenko I, et al.Second opinions from medical oncologists for early-stage breast cancer: Prevalence, correlates, and consequences.JAMA Oncol. 2017;3(3):391-397. doi:10.1001/jamaoncol.2016.5652Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M.Estimation of the number of women living with metastatic breast cancer in the United States.Cancer Epidemiol Biomarkers Prev. 2017;26(6):809-815. doi:10.1158/1055-9965.EPI-16-0889Additional ReadingDeVita, Vincent., et al. Cancer: Principles & Practice of Oncology. Cancer of the Breast. Wolters Kluwer,Hayes D.Patient education: Treatment of metastatic breast cancer (Beyond the Basics).UpToDate.
9 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Liedtke C, Kolberg H.Systemic therapy of advanced/metastatic breast cancer—Current evidence andfFuture concepts.Breast Care. 2016;11(4):275-281. doi:10.1159/000447549Rashid OM, Takabe K.Does removal of the primary tumor in metastatic breast cancer improve survival?J Womens Health (Larchmt). 2014;23(2):184-188. doi:10.1089/jwh.2013.4517Hirata T, Shimizu C, Yonemori K, et al.Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer.Br J Cancer. 2009;101(9):1529-1536. doi:10.1038/sj.bjc.6605360American Cancer Society.Hormone therapy for breast cancer.Larionov AA.Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients.Front Oncol. 2018;8:89. doi:10.3389/fonc.2018.00089Food and Drug Administration.Enhertu label.Chue BM, La Course BD.Case report of long-term survival with metastatic triple-negative breast carcinoma: Treatment possibilities for metastatic disease.Medicine (Baltimore). 2019;98(16):e15302. doi:10.1097/MD.0000000000015302Kurian AW, Friese CR, Bondarenko I, et al.Second opinions from medical oncologists for early-stage breast cancer: Prevalence, correlates, and consequences.JAMA Oncol. 2017;3(3):391-397. doi:10.1001/jamaoncol.2016.5652Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M.Estimation of the number of women living with metastatic breast cancer in the United States.Cancer Epidemiol Biomarkers Prev. 2017;26(6):809-815. doi:10.1158/1055-9965.EPI-16-0889Additional ReadingDeVita, Vincent., et al. Cancer: Principles & Practice of Oncology. Cancer of the Breast. Wolters Kluwer,Hayes D.Patient education: Treatment of metastatic breast cancer (Beyond the Basics).UpToDate.
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Liedtke C, Kolberg H.Systemic therapy of advanced/metastatic breast cancer—Current evidence andfFuture concepts.Breast Care. 2016;11(4):275-281. doi:10.1159/000447549Rashid OM, Takabe K.Does removal of the primary tumor in metastatic breast cancer improve survival?J Womens Health (Larchmt). 2014;23(2):184-188. doi:10.1089/jwh.2013.4517Hirata T, Shimizu C, Yonemori K, et al.Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer.Br J Cancer. 2009;101(9):1529-1536. doi:10.1038/sj.bjc.6605360American Cancer Society.Hormone therapy for breast cancer.Larionov AA.Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients.Front Oncol. 2018;8:89. doi:10.3389/fonc.2018.00089Food and Drug Administration.Enhertu label.Chue BM, La Course BD.Case report of long-term survival with metastatic triple-negative breast carcinoma: Treatment possibilities for metastatic disease.Medicine (Baltimore). 2019;98(16):e15302. doi:10.1097/MD.0000000000015302Kurian AW, Friese CR, Bondarenko I, et al.Second opinions from medical oncologists for early-stage breast cancer: Prevalence, correlates, and consequences.JAMA Oncol. 2017;3(3):391-397. doi:10.1001/jamaoncol.2016.5652Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M.Estimation of the number of women living with metastatic breast cancer in the United States.Cancer Epidemiol Biomarkers Prev. 2017;26(6):809-815. doi:10.1158/1055-9965.EPI-16-0889
Liedtke C, Kolberg H.Systemic therapy of advanced/metastatic breast cancer—Current evidence andfFuture concepts.Breast Care. 2016;11(4):275-281. doi:10.1159/000447549
Rashid OM, Takabe K.Does removal of the primary tumor in metastatic breast cancer improve survival?J Womens Health (Larchmt). 2014;23(2):184-188. doi:10.1089/jwh.2013.4517
Hirata T, Shimizu C, Yonemori K, et al.Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer.Br J Cancer. 2009;101(9):1529-1536. doi:10.1038/sj.bjc.6605360
American Cancer Society.Hormone therapy for breast cancer.
Larionov AA.Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients.Front Oncol. 2018;8:89. doi:10.3389/fonc.2018.00089
Food and Drug Administration.Enhertu label.
Chue BM, La Course BD.Case report of long-term survival with metastatic triple-negative breast carcinoma: Treatment possibilities for metastatic disease.Medicine (Baltimore). 2019;98(16):e15302. doi:10.1097/MD.0000000000015302
Kurian AW, Friese CR, Bondarenko I, et al.Second opinions from medical oncologists for early-stage breast cancer: Prevalence, correlates, and consequences.JAMA Oncol. 2017;3(3):391-397. doi:10.1001/jamaoncol.2016.5652
Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M.Estimation of the number of women living with metastatic breast cancer in the United States.Cancer Epidemiol Biomarkers Prev. 2017;26(6):809-815. doi:10.1158/1055-9965.EPI-16-0889
DeVita, Vincent., et al. Cancer: Principles & Practice of Oncology. Cancer of the Breast. Wolters Kluwer,Hayes D.Patient education: Treatment of metastatic breast cancer (Beyond the Basics).UpToDate.
DeVita, Vincent., et al. Cancer: Principles & Practice of Oncology. Cancer of the Breast. Wolters Kluwer,
Hayes D.Patient education: Treatment of metastatic breast cancer (Beyond the Basics).UpToDate.
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit
Was this page helpful?
Thanks for your feedback!
What is your feedback?OtherHelpfulReport an ErrorSubmit
What is your feedback?
